This article is more than 5 years old. Information may no longer be current.
Vistakon receives approval to market treatment for ocular itching
Click Here to Manage Email Alerts
The U.S. Food and Drug Administration has approved the use of alcaftadine for the prevention of itching associated with allergic conjunctivitis.
According to a release announcing the approval, Lastacaft (alcaftadine ophthalmic solution, 0.25%) will be marketed by Vistakon Pharmaceuticals in 5-mL bottles containing 3 mL of the solution as well as benzalkonium chloride as a preservative.
The drug is approved for once daily use in the prevention of itching associated with allergic conjunctivitis but should not be used for treatment of irritation associated with contact lens wear, the statement said.
In clinical trials, eye irritation, burning or stinging on instillation, eye redness, and eye itchiness were noted in fewer than 4% of treated patients; of nonocular complications, nasopharyngitis, headache and influenza were reported in fewer than 3%.
According to the product's approved label, alcaftadine is an "H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis."
Follow OSNSuperSite.com
on Twitter.